Showing 3731-3740 of 7903 results for "".
Point/Counterpoint: Who Should Perform Middle Segment Surgery?
https://crstoday.com/crst-issues/may-2026/point-counterpoint-who-should-perform-middle-segment-surgery/60830/Soup to Nuts: Cataract Surgical Devices in Your Armamentarium
https://crstoday.com/crst-supplements/soup-to-nuts-cataract-surgical-devices-in-your-armamentarium/soup-to-nuts-cataract-surgical-devices-in-your-armamentarium/45149/A roundtable discussion on how to manage a variety of situations with preferred tools and techniques.Point/Counterpoint: Epithelium on Versus Epithelium off
https://crstoday.com/topics/general/pointcounterpoint-epithelium-on-versus-epithelium-off/42520/Surgeons discuss whether to remove the outer corneal layer during CXL.Descemet Stripping Automated Endothelial Keratoplasty
https://crstoday.com/topics/general/descemet-stripping-automated-endothelial-keratoplasty/42078/Robotics in Ophthalmology
https://crstoday.com/crst-issues/june-2023/robotics-in-ophthalmology/45044/The future of surgery is likely human and robotic collaboration.AI for the Early Detection of Pathology
https://crstoday.com/crst-issues/june-2023/ai-for-the-early-detection-of-pathology/45040/The need for accurate and efficient diagnosis is growing.The Tao of R&D
https://crstoday.com/topics/general/the-tao-of-rd/42858/Was last summer's conflict between Valeant and Allergan emblematic of a new era of innovation-killing corporate consumption, the last gasp of an old age, or something else entirely?Past Lessons, Future Directions
https://crstoday.com/topics/practice-management/past-lessons-future-directions/43503/CRST held a roundtable discussion of private equity in ophthalmology. Participants drew on their experience with physician practice management companies to advise doctors on the consolidation efforts of today.The Positive and Negative Ripple Effects of Expanded IOL Options
https://crstoday.com/crst-issues/feb-2022/the-positive-and-negative-ripple-effects-of-expanded-iol-options/44651/Is having more IOLs to choose from a good or a bad thing?AbbVie: Honoring Its Legacy to Guide Its Future
https://crstoday.com/crst-supplements/abbvie-honoring-its-legacy-to-guide-its-future/abbvie-honoring-its-legacy-to-guide-its-future/45319/Building on 75 years of innovation, AbbVie continues its strong investment in eye care.